New-onset acute ischemic stroke following COVID-19

Najafi, MohammadAmin; Khorvash, Fariborz; Kheradmand, Mohsen; Saadatnia, Mohammad; Chegini, Rojin; Najafi, Farideh

doi:10.4103/jrms.jrms_255_21

Cited by 6 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Katz et al, 2021) The hyperinflammatory response to COVID-19 infection and additional bacterial infections is suggested to be the cause of leukocytosis. Leukocytosisgenerates into inflammatory biomarkers that may be utilized to detect systemic inflammation (Khorvash et al, 2019) ,(Gupta et al, 2020). From the total 24 patients, only 16patients were tested for D-dimer, the resultswere 18.8% had normal D-dimer levels while 81.3% had elevated D-dimer levels.…”

mentioning

confidence: 99%

Profile of Stroke Patients with COVID-19 at Rumah Sakit Islam Surabaya Jemursari, Indonesia

Syifak,

Yuniati,

Surya

et al. 2023

IIMJ

View full text Add to dashboard Cite

Background: Stroke is the number one cause of death in Indonesia, in America stroke is also the number one cause of disability. In COVID-19, most patients experience mild to moderate respiratory symptoms, and need no specific treatment. However, in some patients with comorbidities such as cardiovascular, diabetes mellitus, chronic respiratory disease, and malignancy, it often gives serious manifestation. Objective: This study aimed to profile of stroke patients with COVID-19 at Rumah Sakit Islam Surabaya Jemursari, Indonesia. Method: The type of this research was observational retrospective research. We used all the stroke patient hospitalized at Rumah Sakit Islam Surabaya Jemursari from April to December 2020 that confirmed the diagnosis of COVID-19. We used the general data, data of clinical symptoms, blood pressure, head CT-scan findings, and laboratory findings the data of participants was collected. The data showed as number (frequency) and percentage. Results: The patient’s average age of 57 years, male was common; patients with hypertension were often seen in the comorbidities; ischemic strokes were by far the most prevalent form; subcortical regions were the most frequent location of stroke based on the CT scan. The results of head CT showed that 91.7% of patients had an ischemic stroke and 8.3% of patients had a hemorrhagic stroke. Conclusions: The stroke patients with COVID-19 and hospitalized at Rumah Sakit Islam Surabaya Jemursari, Indonesia have an average age of 57 year, and most of the patient was male. Comorbid hypertension was commonly observed in this study. Based on the type of stroke, ischemic was the most common manifestation and subcortical regions were the most frequent location.

show abstract

mentioning

confidence: 99%

Profile of Stroke Patients with COVID-19 at Rumah Sakit Islam Surabaya Jemursari, Indonesia

Syifak,

Yuniati,

Surya

et al. 2023

IIMJ

View full text Add to dashboard Cite

show abstract

Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults

Lu,

Matuska,

Nadimpalli

et al. 2024

JAMA

View full text Add to dashboard Cite

ImportanceIn January 2023, the US Centers for Disease Control and Prevention and the US Food and Drug Administration noted a safety concern for ischemic stroke among adults aged 65 years or older who received the Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5 COVID-19 bivalent vaccine.ObjectiveTo evaluate stroke risk after administration of (1) either brand of the COVID-19 bivalent vaccine, (2) either brand of the COVID-19 bivalent plus a high-dose or adjuvanted influenza vaccine on the same day (concomitant administration), and (3) a high-dose or adjuvanted influenza vaccine.Design, Setting, and ParticipantsSelf-controlled case series including 11 001 Medicare beneficiaries aged 65 years or older who experienced stroke after receiving either brand of the COVID-19 bivalent vaccine (among 5 397 278 vaccinated individuals). The study period was August 31, 2022, through February 4, 2023.ExposuresReceipt of (1) either brand of the COVID-19 bivalent vaccine (primary) or (2) a high-dose or adjuvanted influenza vaccine (secondary).Main Outcomes and MeasuresStroke risk (nonhemorrhagic stroke, transient ischemic attack, combined outcome of nonhemorrhagic stroke or transient ischemic attack, or hemorrhagic stroke) during the 1- to 21-day or 22- to 42-day risk window after vaccination vs the 43- to 90-day control window.ResultsThere were 5 397 278 Medicare beneficiaries who received either brand of the COVID-19 bivalent vaccine (median age, 74 years [IQR, 70-80 years]; 56% were women). Among the 11 001 beneficiaries who experienced stroke after receiving either brand of the COVID-19 bivalent vaccine, there were no statistically significant associations between either brand of the COVID-19 bivalent vaccine and the outcomes of nonhemorrhagic stroke, transient ischemic attack, nonhemorrhagic stroke or transient ischemic attack, or hemorrhagic stroke during the 1- to 21-day or 22- to 42-day risk window vs the 43- to 90-day control window (incidence rate ratio [IRR] range, 0.72-1.12). Among the 4596 beneficiaries who experienced stroke after concomitant administration of either brand of the COVID-19 bivalent vaccine plus a high-dose or adjuvanted influenza vaccine, there was a statistically significant association between vaccination and nonhemorrhagic stroke during the 22- to 42-day risk window for the Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5 COVID-19 bivalent vaccine (IRR, 1.20 [95% CI, 1.01-1.42]; risk difference/100 000 doses, 3.13 [95% CI, 0.05-6.22]) and a statistically significant association between vaccination and transient ischemic attack during the 1- to 21-day risk window for the Moderna mRNA-1273.222 COVID-19 bivalent vaccine (IRR, 1.35 [95% CI, 1.06-1.74]; risk difference/100 000 doses, 3.33 [95% CI, 0.46-6.20]). Among the 21 345 beneficiaries who experienced stroke after administration of a high-dose or adjuvanted influenza vaccine, there was a statistically significant association between vaccination and nonhemorrhagic stroke during the 22- to 42-day risk window (IRR, 1.09 [95% CI, 1.02-1.17]; risk difference/100 000 doses, 1.65 [95% CI, 0.43-2.87]).Conclusions and RelevanceAmong Medicare beneficiaries aged 65 years or older who experienced stroke after receiving either brand of the COVID-19 bivalent vaccine, there was no evidence of a significantly elevated risk for stroke during the days immediately after vaccination.

show abstract